A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

We'll know more about the company's medium-term prospects by the end of the year.

Case Western Reserve researcher finds new use for revolutionary gene-splicing tool; electrochemical platform could lead to blood test for HPV, parvo or others The gene-editing tool CRISPR has been ...

On June 11, 2025, the U.S. Court of Appeals for the Federal Circuit decided Agilent Technologies, Inc. v. Synthego Corp. (No. 23-2186), addressing enablement of prior art references for disputed ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will summarize the bulls’ thesis on CRSP. CRISPR Therapeutics AG (CRSP)’s share was ...

Scientists have unveiled a CRISPR-based tool, ThermoCas9, capable of pinpointing and removing tumor DNA by detecting cancer-specific chemical markers, potentially sparing healthy cells. In parallel, ...

The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...